John Libbey Eurotext



New injectable hypoglycemic treatments for type 2 diabetes Volume 13, issue 8, Octobre 2017


Centre hospitalier de Colmar, 39, avenue de la Liberté, 68024 Colmar
* Tirés à part
  • Key words: diabetes mellitus, insulin
  • DOI : 10.1684/med.2017.241
  • Page(s) : 350-4
  • Published in: 2017

During the therapeutic escalation of type 2 diabetes, basal insulin is often the first injectable drug prescribed after years of oral treatment. In the 2000s, slow analogues of the insulin, glargine and then detemir, were sold on the market, largely supplanting NPH insulin. Since 2016, the French prescriber has three new specialties: a biosimilar (i.e. a quasi-copy) of glargine, Abasaglar®; a three times more concentrated glargine, Toujeo®; Xutolphy® which is the combination of a new longer-acting analogue, insulin degludec with a GLP-1 analogue, liraglutide.

Assessing the risk of hypoglycemia is a key element in the proper use of basal insulins.